After acquisition by ArcherDX, Baby Genes to be dubbed as ArcherDX Clinical Services

ArcherDX Baby Genes acquisition

This deal will allow ArcherDX to leverage a valuable genetics laboratory in Golden, Colorado

ArcherDX, Inc., a molecular technology company has recently reported the acquisition of Baby Genes, Inc, a Golden, Colorado-based laboratory that focuses on empowering individuals to take charge of their health through genetic insights.

Reportedly, post the acquisition, Baby Genes will continue to operate as a wholly-owned subsidiary under the name ArcherDX Clinical Services, Inc. and the company will continue to market the suite of existing newborn and carrier screening genetic testing services under the Baby Genes brand name.

The Baby Genes acquisition will add substantial new assets to ArcherDX, including the CLIA-certified, CAP accredited genetics laboratory in Golden, Colorado.  The lab is with a test menu including a supplemental newborn screening panel that interrogates over 100 genes covering more than 72 clinically-actionable, inherited conditions as well as pre-defined carrier screening tests that include full-gene sequencing for Cystic Fibrosis (CF), Spinal Muscular Atrophy (SMA) and Fragile X Syndrome. In addition, the laboratory also offers customized confirmatory and reflex genetic testing services to physicians.

The deal is a result of shared commitments

Jason Myers, Co-founder and Chief Executive Officer, ArcherDX, said, “We have a long, positive working relationship with Baby Genes and from day one we saw natural alignment between the two organizations regarding our shared commitment to accelerating the adoption and application of personalized health.”

Jason added, “Archer’s mission is to democratize personalized medicine and decentralization of testing is fundamentally important to the success of personalized medicine because of the efficiencies and accuracies that are gained when testing is done locally. The addition of a CLIA/CAP accredited lab enables our mission, not through centralizing testing, rather to allow us to extend our capabilities in the genetic testing market, improve our ability to understand and anticipate our customers’ needs – especially those customers looking to implement NGS for the first time or expand NGS capabilities, and to enhance our biopharma partner co-development capabilities.”

About the newly dubbed “ArcherDX Clinical Services”

Following the transaction, ArcherDX Clinical Services, Inc. will leverage the existing ArcherDX research and development functions in Boulder, Colorado while all commercial profiling services for both companies will be consolidated in the Golden, Colorado laboratory.

Moreover, Richard Sjogren, previously the Co-founder and Chief Executive Officer at Baby Genes, will be joining ArcherDX’s senior management team as Vice President of operations.

Richard, said, “We are looking forward to working with the broader ArcherDX team to expand the scope and availability of our proactive genetic health tests.” Further, he added, “We see tremendous growth opportunities ahead as we continue to partner with innovative scientists, health care professionals and proactive individuals to make a difference in extending and improving the quality of life.”